Condition: Upper Limb Spasticity · Sponsor: Chongqing Claruvis Pharmaceutical Co., Ltd.
This is a randomized, double-blind, multi-center phase II/III study to evaluate the efficacy and safety of Recombinant Botulinum Toxin Type A (YY001) for injection in the treatment of upper limb spasticity in adults
This description comes directly from the study's public registry record.
Jieru Bai · +86 13883955310 · bai.jieru@claruvis.com
Xiaoyun Sun, Ph.D · +86 13810399273 · sun.xiaoyun@claruvis.com
Always discuss trial participation with your own doctor first.
| Anhui Provincial Hospital | Hefei, Anhui, China | Recruiting |
| The Second People's Hospital of Hefei | Hefei, Anhui, China | Recruiting |
| Peking Union Medical College Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Chongqing Traditional Chinese Medicine Hospital | Chongqing, Chongqing Municipality, China | Recruiting |
| The First Affiliated Hospital of Chongqing Medical University | Chongqing, Chongqing Municipality, China | Recruiting |
| Guangdong Provincial People's Hospital | Guangzhou, Guangdong, China | Recruiting |
| Sun Yat-sen Memorial Hospital | Guangzhou, Guangdong, China | Recruiting |
| Shenzhen Second People's Hospital | Shenzhen, Guangdong, China | Recruiting |
| The First Affiliated Hospital of Henan University | Kaifeng, Henan, China | Recruiting |
| RenMin Hospital Of Wuhan University | Wuhan, Hubei, China | Recruiting |
| Huai'an First People's Hospital | Huai'an, Jiangsu, China | Recruiting |
| The First Affiliated Hospital of Soochow University | Suzhou, Jiangsu, China | Recruiting |
+ 12 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06783114